Allergic Bronchopulmonary Aspergillosis Treated With Itraconazole
To the Editor:
The study reported by Drs. Mroueh Ricketti et al.4 The disease had developed over 6 months to 5 years and was in an exacerbation phase. Nine had severe asthma, and there were no cases of underlying cystic fibrosis. Treatment was carried out during a developing episode of ABPA as defined by clinical and x-ray film signs and a rise in total IgE. Oral itraconazole (200 mg, once daily) was administered for 6 months in ten patients and for a longer period in two. Six patients were on continuous systemic prednisolone (mean dose 16 mg/d, range 10 to 30 mg/d) at the start of therapy, and three of these patients were inhaling corticosteroids.
Response was evaluated at 1,3, 6, and 12 months. A patient was presumed to have responded to therapy when all clinical and x-ray film signs of exacerbation had disappeared, with a decrease of serum IgE and blood eosinophilia.
Eleven patients showed major improvement under itraconazole, whereas no change was noted in one taking itraconazole and corticosteroids. Prednisolone was discontinued in five to six patients 1 to 4 months after inclusion. In 11 of 12 cases, mean blood eosinophilia dropped from 983/mm3 (420 to 1,850) before the start of itraconazole therapy to 467/mm3 (150 to 1,100) at the end of treatment, whereas mean serum IgE for all 12 cases decreased from 2,239 IU/mL (250 to 14,600) to 677 IU/mL (10 to 1,650). Aspergillus specific IgE levels did not seem to reflect clinical response in most cases, and Aspergillus precipitins became negative again in seven cases. Five patients were in clinical relapse 2 to 5 months after therapy was stopped and two at 14 months. There were no adverse clinical or biologic effects.
The cases reported here and in the literature5 indicate that the use of itraconazole as adjunctive therapy generally allows reduction or discontinuance of corticosteroids, which are often administered over long periods in the treatment of ABPA. In six of our patients, remission from a developing episode of ABPA was achieved using intraconazole without corticosteroids. However, randomized studies are required to determine the role of this antifungal drug as an alternative when corticosteroids are contraindicated or during weaning from prolonged corticosteroid therapy or in association with corticosteroids during a developing episode of ABPA to shorten the treatment period. 
